The millions of women who experience bladder leakage now have a new option to strengthen and tone away their problem instead of covering it up with pads.
The PeriCoach System is a discreet device and smartphone app that helps women perform at-home pelvic floor muscle training, exercises recommended by the American College of Physicians as first-line treatment for urinary incontinence. PeriCoach is the only system that includes a web portal allowing clinicians to remotely monitor their patients’ progress.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7543451-pericoach-fda-approval/
A recent study found that only 47% of Americans are currently taking steps to prevent bone loss1, despite considering it to be of high importance. In an effort to educate the public about the importance of bone health, Sunsweet Growers has partnered with the International Osteoporosis Foundation (IOF) to support their annual World Osteoporosis Day (WOD) campaign. WOD is globally celebrated on October 20 and serves to create awareness for bone health and the steps that can be taken to protect bones including incorporating bone-building habits – like eating prunes – into a regular lifestyle routine.
Bones need the right nutrients to stay strong and healthy and research suggests that eating just 5-6 prunes (the Feel Good Fruit!) each day may help to prevent bone loss. However, many do not think about bone health until after a fracture or break occurs.
To view the multimedia release go to:
https://www.multivu.com/players/English/8410051-sunsweet-iof-world-osteoporosis-day-bone-health/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Today’s U.S. healthcare providers face a three-pronged deluge of demands from patients, insurance companies, and the government. To successfully address these new and evolving expectations, members of the medical sector must leverage the capabilities of new wireless technologies – or fall behind their more savvy competitors.
Frost & Sullivan recently published a whitepaper, Mobile Devices and Healthcare: What’s New, What Fits, and How Do You Decide?, which examines the strengths and drawbacks of four major mobile device types – smartphones, tablets, push-to-talk communication devices, and machine-to-machine (M2M) remote medical monitoring devices. Each device category is evaluated for application in three unique environments – the hospital, physician’s office, and the patient’s home. Criteria for selecting a mobility partner are also discussed.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/51532/
On May 27, CVS/pharmacy launched a new in-store fundraising campaign named Advancing Medical Research, to support medical research and help improve the quality of life for those living with amyotrophic lateral sclerosis (ALS) and cystic fibrosis (CF). Funds raised through the campaign will benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research, and the Cystic Fibrosis Foundation, the world’s leader in the search for a cure for cystic fibrosis. Supporters for the 2012 campaign can donate $1 or $3 dollars at the register in CVS/pharmacy locations and online at www.cvs.com/alscff through June 30.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56330-cvs-pharmacy-fundraising-campaign-support-als-and-cystic-fibrosis
CVS Health (NYSE:CVS), the nation’s largest pharmacy innovation company, today announced Be The First, a five-year $50 million initiative to help deliver the nation’s first tobacco-free generation. Through this initiative, which is funded through CVS Health and the CVS Health Foundation, the company is extending its commitment to help people lead tobacco-free lives. Recognizing that tobacco use is the leading preventable cause of disease and death in the United States and that youth use of some tobacco products is on the rise, Be The First comprises comprehensive education, advocacy, tobacco control and healthy behavior programming in partnership with organizations uniquely positioned to tackle this public health challenge.
“We are at a critical moment in our nation’s efforts to end the epidemic of tobacco use that continues to kill more people than any other preventable cause of death, and threatens the health and well-being of our next generation,” said Troyen A. Brennan, M.D., M.P.H., and Chief Medical Officer for CVS Health. “Ensuring our youth stay tobacco-free requires increased education and awareness of healthy behaviors. We’re partnering with experts across the public health community who have established best practices to help prevent tobacco use. And, by establishing more public-private partnerships to implement these strategies more aggressively, we can help increase the number of people leading tobacco-free lives and move us one step closer to delivering the first tobacco-free generation.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7775151-cvs-health-be-the-first/
Cutanea Life Sciences, Inc. (CLS), an emerging U.S. prescription product development company, formally unveiled its new digital presence, www.cutanea.com, to the dermatology community in conjunction with this winter’s annual gathering of dermatologists from the U.S and around the world. CLS has a stream of innovative product candidates in different stages of development that cover an array of skin conditions, including acne, rosacea, psoriasis and warts caused by human papillomavirus (HPV).
CLS’s new digital presence demonstrates the company’s intent to change the way that customers think about a valued dermatology partner. CLS believes that it can make an impact in the current state of dermatology practice through its commitment to focus on unmet and underserved patient needs. In turn this will help medical professionals optimize their practice time through CLS products and services.
To view the multimedia release go to:
http://www.multivu.com/players/English/7743651-cutanea-life-sciences-dermatology/
An expert group of specialists have come together to develop three new educational resources: the Journal of Perioperative Medicine, the Journal of Neonatal Intensive Care and an open-access online portal. These resources provide practical advice on key clinical issues, tackle controversial topics on which a consensus is needed, and highlight clinical concerns that need to be addressed in clinical practice. These resources are available through a new educational initiative called Cure&Care and are accessible at: www.cureandcareportal.com. Cure&Care officially launches at Euroanaesthesia 2014, in Stockholm, Sweden, 30 May – 3 June.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400535-cure-care-new-educational-initiative
Blood is an essential component for life, but many people do not think about it until the need is critical. Each year 234 million major operations are performed worldwide, many involving blood transfusions or treatments resulting in a continuous need for donations.
That’s why Abbott (NYSE: ABT) and Real Madrid soccer star Cristiano Ronaldo are partnering to bring even more attention to this important cause. Regarded as one of the top soccer players in the world, Ronaldo will serve as the first global ambassador for the BE THE 1™ movement – developed to inspire young people around the world to regularly donate blood.
“We can all make a difference by donating blood. Each donation can benefit up to three people in emergency situations and for long-term medical treatments,” said Cristiano Ronaldo, forward for Real Madrid and Captain for Portugal National Football. “That’s why I am enthusiastic to be partnering with Abbott to bring awareness to the importance of blood donation and to encourage people around the world to become lifelong blood donors and help save lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7668251-abbott-cristiano-ronaldo-donate-blood/
Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis.
Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease.
“As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
